Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
暂无分享,去创建一个
J. Reid | A. Lièvre | P. Laurent-Puig | M. Ychou | M. Ducreux | F. Penault-Llorca | P. Rougier | V. Boige | O. Bouché | F. Bibeau | E. Buc | S. Stone | B. Landi | J. Bachet | A. Cayre | G. Manceau | T. Lecomte
[1] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Siannis,et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.
[3] E. Van Cutsem,et al. Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study , 2008, Clinical Cancer Research.
[4] Andrew J. Wilson,et al. Erratum: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. (Cancer Res (2008) 68 (1953-61)) , 2008 .
[5] G. Fountzilas,et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study , 2008, BMC Cancer.
[6] R. Herbst,et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Jänne,et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients , 2008, British Journal of Cancer.
[8] Pierre Laurent-Puig,et al. Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.
[9] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Sanjay Goel,et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.
[11] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] A. Italiano,et al. Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors for Which FISH Analysis Does Not Detect an Increase in EGFR Gene Copy Number , 2008, Annals of Surgical Oncology.
[13] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] F. Cavalli,et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.
[15] M. Moroni,et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] F. Blanchard,et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.
[19] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[20] Jennifer Herrick,et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. , 2006, Journal of the National Cancer Institute.
[21] E. Van Cutsem,et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] F. Cappuzzo,et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[24] M. Moroni,et al. Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[26] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[27] S. Groshen,et al. Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[29] E. Rowinsky. Targeting the molecular target of rapamycin (mTOR) , 2004, Current opinion in oncology.
[30] E. Van Cutsem,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[31] William R Sellers,et al. The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[33] C. Morrison,et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer , 2004, Oncogene.
[34] G. Deng,et al. BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.
[35] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[36] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[37] G. Mills,et al. Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .
[38] S. Andreola,et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] P. Jänne,et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.